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ABSTRACT 
The aim of present study was to formulate & evaluate the mucoadhesive sustained release formulations of lamivudine. And to fulfil this aim, 
two mucoadhesive formulations- gels and tablets were prepared by using three different polymers: HPMC K15, poloxamer 407 & carbopol 934. 
Three mucoadhesive gel and nine tablet formulations were prepared and evaluated for various parameters. All prepared gel & tablet 
formulations had good physico-mechanical properties. Among all the formulations, carbopol gel and tablets showed the highest mucoadhesive 
force, although, each formulation had good adhesive force.  All three gels were able to give sustained release up to 12 hours. Tablet 
formulations, so from this study, it is concluded that mucoadhesive formulations of lamivudine can be prepared for sustaining its release. And 
the successful outcome of the present study also encourage for further studies to assess the ability of the mucoadhesive formulations of 
lamivudine in providing an effective sustained and safe therapy for AIDS.  
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INTRODUCTION 
 In our present work we are preparing two different types of 
mucoadhesive formulations-mucoadhesive gel and 
mucoadhesive tablets. 
Mucoadhesive gel formulation was selected as it is a 
semisolid dosage form, has advantage of easy dispersion 
throughout the mucosa & ease of preparation. However, 
drug dosing from semisolid dosage forms may not be as 
accurate as from tablets, patches, or films. Poor retention of 
the gels at the site of application has been overcome by using 
bioadhesive formulations. Certain bioadhesive polymers, e.g. 
poloxamer 407, sodium carboxymethylcellulose, carbopol, 
hyaluronic acid, and xanthan gum, undergo a phase change 
from a liquid to a semisolid.  
(Mucoadhesive) Tablets may be defined as solid 
pharmaceutical dosage forms containing drug substances 
with or without suitable diluents and prepared by either 
compression or molding methods. They have been in 
widespread use since the latter part of the 19th century, and 
their popularity continues. Tablets remain popular as a 
dosage form because of the advantages afforded both to the 
manufacturer (e.g., simplicity and economy of preparation, 
stability and convenience in packaging, shipping, and 
dispensing) and the patient (eg, accuracy of dosage, 
compactness, portability, blandness of taste, and ease of 
administration) (Gennaro et al., 2000) .  
MATERIALS AND METHOD 
List of ingredients used in preparation of gel and tablet 
formulations.
 
Sr. no. Ingredients Source 
1. Lamivudine Strides Arcolab Limited (Bangalore, India). 
2. Carbopol 934 Coral Pharma  (Gujrat). 
3. Poloxamer 407 BASF Corp. (Ludwigshafen, Germany) 
4. HPMC K15 Colorcon Asia Pvt. Ltd., Verna, Goa, India 
5. Lactose Sisco Research Lab., Mumbai, India. 
6. Talc Oxford Laboratory Pvt. Ltd., Mumbai, India. 
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Methods of preparation of mucoadhesive gels: 
Preparation of lamivudine gel by using HPMC K15: 
2%, 4%, 6%, 8%, 10% & 12%, plane gel formulation of HPMC 
K15 were prepared in distilled water by simple mixing 
method. 12%, formulation was selected on the bases of 
consistency of gel. Lamivudine (150mg) was dissolved in 
small amount of distilled water and then incorporated in 
12% HPMC gel with continuous stirring. After that, set aside 
the formulation for some time at room temperature. 
Preparation of Lamivudine gel by using Corbopol 934: 
0.5, 1% & 2%, plane gel formulation of Carbopol were 
prepared in distilled water. Out of these, 1% gel formulation 
was selected on the bases of gel consistency. As on 
incorporation of lamivudine (150mg), the formulation was 
precipitated. Therefore 0.5% gel was selected to get the 
desired gel formulation. And gel was prepared by simply 
adding the lamivudine (already dissolved in small amount of 
water) into 0.5% carbopol gel, with continuous stirring. 
Preparation of Lamivudine gel by using Poloxamer 407:  
The pluronic gels were prepared by modification of the “Cold 
dispersion” method described by Schmolka. The weighed 
amount of poloxamer (1g) was placed in beaker and left in an 
oven at 110°C for 15 minutes to obtain a homogeneous 
liquefied mixture then 150mg lamivudine (which was 
already dissolved in small amount of water) added with 
continuous stirring. The solution was cooled to room 
temperature, & beaker was left in a refrigerator until a clear 
solution was obtained. The gel was formed when the solution 
was brought back to room temperature and stored at 
ambient temperature prior to use. 
Formulation of mucoadhesive tablets: 
Mucoadhesive tablets of Lamivudine were made by direct 
compression method. Nine formulations (F1-F9) were 
formulated by using three different mucoadhesive polymers 
(HPMC K15, Carbopol 934 & Poloxamer 407). Mucoadhesive 
polymers were used as binder, lactose as diluents and talc as 
lubricant. 
The mucoadhesive tablets were prepared by mixing of drug 
with binder, in a pestle and mortar until homogenized. Then 
all other excipients were added. Mixture was passed through 
sieve no. 60. Finally the blend was compressed using the 
round concave punches (10.3mm in diameter) and dies by 
rotary tablet punching machine. The tablet weight was 
adjusted to 500mg and 75 tablets for each batch were 
prepared.  Formula for nine batches is given in table 1. 
 
Table 1: formula for different tablet formulations. 
INGREDENTS 
(mg) 
FORMULATION 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
Drug (Lamivudine) 150 150 150 150 150 150 150 150 150 
HPMC K 15 100 150 200 - - - - - - 
Carbopol 934 - - - - - - 20 30 40 
Poloxamer 407 - - - 75 125 175 - - - 
Lactose 230 180 130 255 205 155 310 300 290 
Talc 20 20 20 20 20 20 20 20 20 
 
RESULT & DISCUSSION 
 Preliminary Investigation of Drug (Lamivudine):  
1. PHYSICAL APPEARANCE 
Lamivudine was white color powder.  
2. MELTING POINT 
Melting point of lamivudine was found to be 161°C. 
3. SOLUBILITY STUDY 
4. Solubility profile of lamivudine in various solvents, are 
given in table 2. 
Table 2: Solubility profile of Lamivudine in various 
solvents 
S. No. Solvent Solubility 
1. Distilled water + 
2. Ethanol + 
3. Methanol + 
4. Acetone - 
5. Chloroform - 
6. Ethyl acetate - 
7. 0.1N HCl + 
8. 0.1 N NaOH + 
λ max OF LAMIVUDINE: 
λ max of lamivudine was found to be 271.5 nm in distilled 
water. 
 
Figure 1: Scanning of Lamivudine in UV range 
Standard curve of lamivudine 
Standard calibration curve of lamivudine was determined by 
plotting absorbance v/s concentration on double beam U.V. 
spectrophotometer using λ max = 271.5 nm. Straight line 
was obtained after plotting concentration on X axis. It 
follows the beer’s law. As beer’s law is concentration 
dependent and on increasing the concentration from 5μg/ml 
to 30μg/ml, gave liner increase in absorbance. The 
regression equation was y = 0.0247x + 0.0093, which was 
further used for calculation of concentration of unknown 
samples. The R2 value of standard curve was 0.9978, which 
signify that plot was linear.  The results are shown in table 3 
and figure 8. 
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Table 3: Absorbance of Lamivudine in distilled water at 
λmax 271.5 nm 
S. No. Concentration(µg/ml) Absorbance 
(nm)±(SD) 
1. 0 0 
2. 5 0.116±0.002 
3. 10 0.238±0.001 
4. 15 0.334±0.003 
5. 20 0.493±0.002 
6. 25 0.613±0.002 
7. 30 0.738±0.001 
 
Evaluation parameter for mucoadhesive gels: 
General Appearance: All three gel formulations were good 
texture profile. They were transparent in appearance and no 
sign of grittiness was observed. 
Mucoadhesive force 
Mucoadhesive force of all three gel formulations were 
determined by using goat stomach mucosa and is given in 
table 10. Out of all three polymers, Carbopol showed the 
maximum mucoadhesive force. 
Table 4: Mucoadhesive force of polymers used in gel 
formulations. 
S. N. Polymers Mucoadhesive force (dyne/cm²) 
1. Poloxamer 407 2.2455 
2. HPMC K15 2.6271 
3. Carbopol 934 3.3618 
 
Drug Release Study 
Drug release study data of all three gels are shown in table 4 
Figure 2. 
 
Table 5:  Data of Release profile of formulated gels. 
Zero order 
R² 
First order 
R² 
Higuchi 
R² 
Korsmeyer- peppas 
R² n 
0.9597 0.9568 0.8883 0.981 1.1678 
 
The above drug release data & plot show that the prepared gel formulations released drug up to 12 hours and more or less, all 
three gel formulations were giving sustained drug release profile. These gel formulations were further studied to know the drug 
release kinetics. 
Drug release kinetic study: 
1. HPMC K15 gel 
Table 6:  Data for drug release kinetic study of HPMC K15 gel 
Time 
(hr) 
Square 
root of 
time 
Log time Cumulative % 
drug released 
Log (Mt/M∞) Cumulative % 
drug remaining 
to release 
Log  cumulative % 
drug remaining to 
release 
0 0 - 0 - 100 2 
1 1 0 18.43 1.2655 81.57 1.9115 
2 1.414 0.301 37.45 1.5734 62.55 1.7962 
3 1.732 0.477 46.45 1.6669 53.55 1.7287 
4 2 0.602 64.07 1.8066 35.93 1.5554 
5 2.236 0.6989 73.56 1.8666 26.44 1.4222 
6 2.449 0.778 83.92 1.9238 16.08 1.2062 
7 2.645 0.845 87.12 1.9401 12.88 1.1099 
8 2.828 0.903 91.32 1.9605 8.68 0.9385 
10 3.162 1 94.22 1.9741 5.78 0.7619 
12 3.464 1.079 97.89 1.9907 2.11 0.3242 
Zero order 
R² 
First order 
R² 
Higuchi 
R² 
Korsmeyer- peppas 
R² n 
0.8538 0.9896 0.9598 0.9488 0.6792 
 
Time (hr) Cumulative % drug release 
HPMC K15 gel Poloxamer 407 gel Carbopol 934 gel 
0 0 0 0 
1 18.43±1.5 12.92±2.3 4.62±1.9 
2 37.45±2.7 27.63±2.8 13.83±3.4 
3 46.45±3.8 36.6±3.5 18.8±2.2 
4 64.07±2.4 47.43±2.2 25.02±1.5 
5 73.56±4.2 59.82±3.1 34.87±1.7 
6 83.92±2.8 66.01±4.3 42.09±2.9 
7 87.12±2.1 72.32±2.4 61.83±2.6 
8 91.32±1.6 79.71±1.8 67.63±1.8 
10 94.22±1.2 83.87±1.2 73.98±2.3 
12 97.89±0.6 88.95±0.88 78.38±1.4 
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On the basis of R² values of above release kinetic plots, it was 
determined that the HPMC gel follows first order drug 
release kinetic model. As R² value of first order, 0.9896 was 
highest among all. And in Korsmeyer- peppas plot, n= 0.6792 
(i.e. 0.45<n<0.89), indicates anomalous diffusion or non-
fickian diffusion. That means, release rate of the HPMC gel 
was controlled by the combination of both, diffusion and 
erosion release mechanism.  
Poloxamer 407 gel 
 
Table 6:  Data for drug release kinetic study of poloxamer 407 gel 
Time 
(hr) 
Square 
root of 
time 
Log time Cumulative % 
drug released 
Log (Mt/M∞) 
 
Cumulative % 
drug 
remaining to 
release 
Log  cumulative % 
drug remaining to 
release 
0 0 - 0 - 100 2 
1 1 0 12.92 1.1112 87.08 1.9399 
2 1.414 0.301 27.63 1.4413 72.37 1.8595 
3 1.732 0.477 36.6 1.5634 63.4 1.8020 
4 2 0.602 47.43 1.6760 52.57 1.7207 
5 2.236 0.6989 59.82 1.7768 40.18 1.6040 
6 2.449 0.778 66.01 1.8196 33.99 1.5313 
7 2.645 0.845 72.32 1.8615 27.68 1.4421 
8 2.828 0.903 79.71 1.9015 20.29 1.3072 
10 3.162 1 83.87 1.9236 16.13 1.2076 
12 3.464 1.079 88.95 1.9491 11.05 1.0433 
Zero order 
R² 
First order 
R² 
Higuchi 
R² 
Korsmeyer- peppas 
R² n 
0.9211 0.9945 0.9695 0.9725 0.7836 
 
On the basis of R² values of above release kinetic plots, it was 
determined that the poloxamer gel follows first order drug 
release kinetic model. As R² value of first order, 0.9945 was 
highest among all. And in Korsmeyer- peppas plot, n= 0.7836 
(i.e. 0.45<n<0.89), indicates anomalous diffusion or non-
fickian diffusion. That means, release rate of the poloxamer 
gel was controlled by the combination of both, diffusion and 
erosion release mechanism. 
On the basis of R² values of above release kinetic plots, it was 
determined that the carbopol gel follows zero order drug 
release kinetic model. As R² value of zero order, 0.9597 was 
highest among all. And in Korsmeyer- peppas plot, n= 1.1678 
(i.e. higher than 0.89), indicates super case II transport. As 
per super Case II transport mechanism, the release 
mechanism was not significantly influenced by formulation 
variables swelling dispersed within a glassy polymer. 
Initially the polymer begin to swell in contact of water, .as 
the penetrant enters the glassy polymer , the glass transition 
temperature of the polymer is lowered and become rubbery 
show diffusion allowing relaxation of macromolecular chains 
and drug diffuse out from the swollen rubbery area of 
polymer wall (Bhowmik B.B. et al, 2009). 
Evaluation parameter for mucoadhesive tablets: 
GENERAL APPEARANCE 
General appearance was examined by visual inspection. All 
tablets were good in appearance; they were white colored 
oval shaped tablets with smooth surface texture and no 
pinholes were observed. 
WEIGHT VARIATION 
 All nine tablet batches passed the weight variation test as 
percentage weight variation was within the pharmacopoeia 
limits (±5%).  Results are shown table 16. 
 
Table 7: weight variation. 
BATCH CODE WEIGHT VARIATION  
(mg) (N=20) 
RESULT 
F1 498±1.9 PASSED 
F2 497±2.6 PASSED 
F3 502±1.76 PASSED 
F4 499±1.6 PASSED 
F5 501±2.8 PASSED 
F6 497±2.9 PASSED 
F7 496±3.3 PASSED 
F8 500±1.88 PASSED 
F9 498±2.3 PASSED 
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THICKNESS  
Thickness of all tablet batches is given in table 8. The 
thickness of the tablets was found in the range of 5.6– 6.1 
mm. 
Table 8: Thickness of tablets. 
BATCH CODE THICKNESS (mm) 
(N=6) 
F1 5.8±0.18 
F2 5.9±0.177 
F3 6.1±0.076 
F4 6±0.11 
F5 5.8±0.2 
F6 5.9±0.16 
F7 5.8±0.084 
F8 6±0.15 
F9 5.9±0.23 
 
FRIABILITY 
The friability of all nine batches is given in table 18. 
Friability of tablets was observed in acceptable range of 
0.34-0.84%. It was within the pharmacopeia limit i.e. less 
than 1%. That means all tablets had good mechanical 
strength. 
Table 9: Friability of tablets. 
BATCH CODE FRIABILITY (%) (N=20) 
F1 0.84 
F2 0.76 
F3 0.72 
F4 0.69 
F5 0.63 
F6 0.56 
F7 0.48 
F8 0.46 
F9 0.34 
 
HARDNESS   
Hardness of all batches is given in table 10. Hardness of the tablets was found in the range of 6.8-9.4 kg/cm2. That was 
satisfactory for sustained release formulations and also indicates good mechanical strength to withstand physical and 
mechanical stress conditions while handling. 
Table 10: Hardness of tablets. 
BATCH CODE HARDNESS(kg/cm2)  
(N=6) 
F1 6.9±0.15 
F2 7.6±0.42 
F3 8.4±0.34 
F4 7.2±0.22 
F5 7.6±0.288 
F6 8.2±0.37 
F7 7.3±0.15 
F8 8.8±0.137 
F9 9.3±0.15 
 
SWELLING INDEX 
Swelling studies were performed till 20 min because after that carbopol tablets started forming soft gel, which was difficult to 
handle and HPMC & poloxamer formulations showed erosion (but poloxamer tablets erode slowly then HPMC tablets). Results 
are given in table. 
 Table 11: Swelling studies of tablets. 
BATCH CODE %  swelling index (±SD) (N=3) 
Time (mins) 
1 10 20 
F1 10.2±2.3 18.6±3.7 32.1±4.2 
F2 12.4±1.8 20±3.4 46.3±2.5 
F3 15.1±2.4 24.6±2.1 54.2±3.6 
F4 13.4±2.2 21.3±4.2 43.5±2.8 
F5 17.7±1.5 32.3±5.1 49.6±2.3 
F6 22.2±2.5 40.2±3.6 57.2±4.3 
F7 27.4±1.2 75±2.6 97.7±3.8 
F8 36.7±2.4 84.6±2.1 102±4.1 
F9 39.2±1.7 90.3±3.4 116±3.3 
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1. MUCOADHESIVE STUDIES 
Mucoadhesive strength of tablets was measured on the modified physical balance as described earlier. The highest adhesion 
force and highest strength of the mucoadhesive bond was observed with the carbopol formulations. And it was increasing with 
increase in concentration of polymer. 
 
Table 12: Mucoadhesive strength & force of tablets. 
BATCH CODE  MUCOADHESIVE STRENGTH  (g) ±SD MUCOADHESIVE FORCE (N) 
F1 17.3±1.4 0.170 
F2 21.9±0.95 0.215 
F3 24.6±0.74 0.241 
F4 20.4±1.2 0.201 
F5 23.5±1.5 0.231 
F6 27.4±0.99 0.269 
F7 33.2±2.2 0.326 
F8 37.5±2.3 0.368 
F9 42.8±1.8 0.417 
 
CONCLUSION 
The aim of present study was to formulate & evaluate the 
mucoadhesive sustained release formulations of lamivudine. 
And to fulfill this aim, two mucoadhesive formulations- gels 
and tablets were prepared by using three different 
polymers: HPMC K15, poloxamer 407 & carbopol 934. Three 
mucoadhesive gel and nine tablet formulations were 
prepared and evaluated for various parameters.  
All prepared gel & tablet formulations had good physico-
mechanical properties. Among all the formulations, carbopol 
gel and tablets showed the highest mucoadhesive force, 
although, each formulation had good adhesive force.  All 
three gels were able to give sustained release up to 12 hours. 
Tablet formulations, F1 to F5 failed to fulfill the aim. Only F6, 
F7, F8 & F9 formulations were selected, as all gave sustained 
release up to 12 hours, except F6, which gave sustained 
release profile only till 7 hours. From the drug release plots, 
it was concluded that the type of polymer and concentration 
of polymer have distinct effect on in vitro drug release 
profile. This can further be justified with in vivo studies. And 
all the formulations follow first order mechanism with 
anomalous diffusion or non-fickian diffusion, except 
carbopol gel and poloxamer tablets. Carbopol gel follows 
zero order release rate with super case II transport and 
poloxamer tablets (F6) follow higuchi with non-fickian 
diffusion. 
So from this study, it is concluded that mucoadhesive 
formulations of lamivudine can be prepared for sustaining 
its release. And the successful outcome of the present study 
also encourage for further studies to assess the ability of the 
mucoadhesive formulations of lamivudine in providing an 
effective sustained and safe therapy for AIDS.  
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